Tim Chiang
Stock Analyst at Capital One
(1.07)
# 3,689
Out of 4,906 analysts
21
Total ratings
31.25%
Success rate
-5.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Chiang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics | Initiates: Overweight | $6 | $1.92 | +212.50% | 1 | Apr 23, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | n/a | $55.22 | - | 3 | Oct 30, 2023 | |
| JSPR Jasper Therapeutics | Initiates: Overweight | $70 | $3.21 | +2,080.69% | 1 | Aug 11, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Overweight | $44 | $21.18 | +107.74% | 2 | Jul 29, 2022 | |
| KALA KALA BIO | Maintains: Outperform | $300 → $200 | $5.70 | +3,408.77% | 2 | Mar 30, 2022 | |
| PCRX Pacira BioSciences | Maintains: Market Perform | $75 → $66 | $22.18 | +197.57% | 3 | May 5, 2021 | |
| RPTX Repare Therapeutics | Initiates: Outperform | n/a | $1.50 | - | 1 | Oct 28, 2020 | |
| VRCA Verrica Pharmaceuticals | Initiates: Outperform | $21 | $0.77 | +2,630.46% | 1 | Jun 24, 2020 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Neutral | n/a | $16.31 | - | 6 | Sep 17, 2018 | |
| SMMT Summit Therapeutics | Initiates: Buy | $33 | $26.34 | +25.28% | 1 | Feb 13, 2018 |
Heron Therapeutics
Apr 23, 2024
Initiates: Overweight
Price Target: $6
Current: $1.92
Upside: +212.50%
Protagonist Therapeutics
Oct 30, 2023
Initiates: Overweight
Price Target: n/a
Current: $55.22
Upside: -
Jasper Therapeutics
Aug 11, 2023
Initiates: Overweight
Price Target: $70
Current: $3.21
Upside: +2,080.69%
Amphastar Pharmaceuticals
Jul 29, 2022
Initiates: Overweight
Price Target: $44
Current: $21.18
Upside: +107.74%
KALA BIO
Mar 30, 2022
Maintains: Outperform
Price Target: $300 → $200
Current: $5.70
Upside: +3,408.77%
Pacira BioSciences
May 5, 2021
Maintains: Market Perform
Price Target: $75 → $66
Current: $22.18
Upside: +197.57%
Repare Therapeutics
Oct 28, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.50
Upside: -
Verrica Pharmaceuticals
Jun 24, 2020
Initiates: Outperform
Price Target: $21
Current: $0.77
Upside: +2,630.46%
Teva Pharmaceutical Industries
Sep 17, 2018
Upgrades: Neutral
Price Target: n/a
Current: $16.31
Upside: -
Summit Therapeutics
Feb 13, 2018
Initiates: Buy
Price Target: $33
Current: $26.34
Upside: +25.28%